Related Experiment Video

Updated: Nov 4, 2025

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.8K

Recent advancements of antiangiogenic combination therapies in ovarian cancer

Daniel An1, Susana Banerjee2, Jung-Min Lee1

  • 1Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Cancer Treatment Reviews
|May 29, 2021
PubMed

Insights

Ovarian cancer treatments are improving, but long-term success is difficult. Understanding drug resistance and sensitivity pathways helps identify new drug combinations to improve patient outcomes.

Area of Science:

  • Oncology
  • Cancer Research
  • Pharmacology

Background:

  • Ovarian cancer remains a significant cause of cancer-related mortality.
  • Despite advances, achieving durable clinical responses to therapy is challenging.
  • Biomarker and genetic analyses are revealing complex resistance and sensitivity pathways.

Purpose of the Study:

  • To review mechanisms of angiogenic response and antiangiogenic therapy in ovarian cancer.
  • To explore interactions between antiangiogenic therapy, the immune system, and DNA damage response pathways.
  • To discuss clinical trial data on combination therapies.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of mechanisms underlying therapeutic resistance and sensitivity.
  • Synthesis of data from clinical trials involving combination therapies.

Main Results:

  • Identification of key pathways influencing response to ovarian cancer therapies.
  • Understanding of how antiangiogenic agents interact with immune and DNA damage response pathways.
  • Evidence from clinical trials exploring combinations of antiangiogenics, PARP inhibitors, and immune checkpoint inhibitors.

Conclusions:

  • Targeting angiogenic pathways holds promise for ovarian cancer treatment.
  • Combination therapies involving antiangiogenics, PARP inhibitors, and immunotherapy may improve outcomes.
  • Further clinical trials are needed to optimize these novel therapeutic strategies.
Keywords:
Combination therapyImmunotherapyOvarian cancerPARP inhibitorVEGF/VEGFR inhibitor

More Related Videos

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.3K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
798
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K